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ABSTRACT
Objective Conjunctivitis has been reported in people 
suffering from COVID-19. However, many ocular symptoms 
are associated with the term ‘conjunctivitis’ which may be 
misleading. It is also unknown whether ocular symptoms 
were different in chronic sufferers of anterior eye diseases, 
when they were experienced or how long they lasted for 
compared with other COVID-19 symptoms.
Methods An online structured questionnaire obtained 
self- report data from people who had a confirmed 
diagnosis of COVID-19. Data for the type, frequency 
and duration of different COVID-19 symptoms were 
ascertained. Anterior eye symptoms experienced by 
participants in the pre- COVID-19 state were compared 
with during the COVID-19 state.
Results Data from 83 participants showed that the most 
reported COVID-19 symptoms were dry cough (66%), 
fever (76%), fatigue (90%) and loss of smell/taste (70%). 
The three most common ocular symptoms experienced 
by participants were photophobia (18%), sore eyes (16%) 
and itchy eyes (17%). The frequency of sore eyes was 
significantly higher (p=0.002) during COVID-19 state 
(16%) compared with pre- COVID-19 state (5%). There 
were no differences between males and females (p>0.05). 
81% of participants reported to have experienced ocular 
symptoms within 2 weeks of other COVID-19 symptoms, 
and 80% reported they lasted for less than 2 weeks.
Conclusion The most significant ocular symptom 
experienced by people suffering from COVID-19 was sore 
eyes. Other symptoms associated with other types of 
conjunctivitis, such as mucous discharge and gritty eyes 
linked to bacterial infection, did not reach significance. The 
term ‘conjunctivitis’ is too broad and should be used with 
caution.
INTRODUCTION
SARS- CoV-2 is the cause of COVID-19, which 
has been shown to be primarily a respiratory 
illness, with the most common symptoms 
being a new continuous cough and high 
temperature. Further symptoms have been 
added to this list, and the WHO added 
conjunctivitis a less common symptom.1 
Ocular manifestations of COVID-19 have not 
been at the forefront of substantial research, 
possibly due to the life- threatening nature 
of the other more serious respiratory symp-
toms which have resulted in high numbers of 
mortality around the world. This might have 
resulted in other non- life- threatening symp-
toms not given importance in the presence of 
other life- threatening conditions. However, 
the type, frequency and ocular transmission 
of the virus must not be ignored, especially as 
Key messages
What is already known about this subject?
 ► To date, there are no studies that have investigated: 
(1) which of the many ocular symptoms are most 
frequently experienced by people suffering from 
COVID-19, (2) whether people who report ocular 
symptoms during COVID-19 were already chron-
ic long- term sufferers of an anterior eye condition, 
(3) how long the ocular symptom lasted for, and (4) 
whether the ocular symptoms occurred at the same 
time as other known COVID-19 symptoms.
What are the new findings?
 ► In people with a positive COVID-19 diagnosis, the 
three most common new symptoms experienced 
by participants were photophobia (18%), sore eyes 
(16%) and itchy eyes (17%). The frequency of sore 
eyes was significantly higher during COVID-19 state 
compared with pre- COVID-19 state. Eighty- one per 
cent of participants who had experienced an eye 
symptom reported to have suffered from it within 
2 weeks of other COVID-19 symptoms, and 80% re-
ported they lasted for less than 2 weeks.
How might these results change the focus of 
research or clinical practice?
 ► Knowledge of which ocular symptom manifests 
during COVID-19 is important, especially for coun-
tries that rely on self- report of COVID-19 symptoms. 
The term ‘conjunctivitis’ is too broad and does not 
differentiate between its different manifestations 
that may mislead and therefore should be used with 
caution.
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the eye has been recognised as one of the organs through 
which the virus might enter the body.
Reports on ocular manifestations are varied and show 
a wide range in terms of prevalence, varying from 4% to 
31% of ocular symptoms among those with a confirmed 
case of the virus.2–4 A systematic review and meta- analysis 
of 15 studies involving 1533 patients reported conjuncti-
vitis as the most common ocular finding.5 It is likely that 
ocular manifestations were not given consideration in the 
presence of other more critical symptoms when patients 
were admitted to hospital.2 3 One study of 56 patients 
with COVID-19 reported that 15 people (27%) had 
ocular symptoms that included sore eyes, itching, foreign 
body sensation, hyperaemia, floaters and/or secretions 
(although the type of secretions was not noted), with six 
patients reporting ocular symptoms prior to other respi-
ratory or fever symptoms onset.6 A larger study in China, 
on 534 confirmed COVID-19 cases, reported a much 
smaller percentage (5%) of people with ocular manifes-
tations.7 The three main ocular symptoms noted were dry 
eye, foreign body sensation and blurred vision. A small 
number of patients (n=3) had reported ocular symp-
tom(s) as their first symptom. In both studies, a positive 
association was reported between the disease severity and 
the prevalence of ocular manifestations.6 7 Further, late- 
onset (>2 weeks after initial influenza symptoms) ocular 
manifestations were reported in a patient who had a 
confirmed COVID-19 in France, as pseudomembranous 
and haemorrhagic conjunctivitis.8 However, conjunctival 
swabs were returned as negative for both bacterial and 
viral manifestations in this patient. Other studies have 
reported the presence of SARS- CoV-2 virus in conjunc-
tival swabs in people suffering from ocular manifestations, 
and also in those who did not manifest with any ocular 
symptoms.9 10 It is further possible that under- reporting 
might have occurred in the absence of any ocular signs 
and no conjunctival swabs were considered necessary.10 
One study even suggested ocular symptoms may be the 
sole symptom of COVID-19.11 As ocular manifestations 
are not considered as serious as the other life- threatening 
symptoms of COVID-19, it is possible that they were 
under- reported in the light of other more serious symp-
toms.12
Early in the pandemic, ocular transmission of 
SARS- CoV-2 was not thought to be a possibility. However, 
a study investigating a previous coronavirus outbreak 
(Middle East respiratory syndrome coronavirus) suggests 
that people who wore full protective wear, including eye 
protection, showed no evidence of serum antibodies.13 
In contrast, people who wore full personal protective 
equipment but no eye protection were infected with 
SARS- CoV-2.10 14
It would be important to ascertain which ocular 
conjunctival symptoms are reported most frequently. 
Conjunctivitis manifests with different aetiologies and 
ocular symptoms, including mucopurulent discharge 
and itchy eyes associated with bacterial and viral conjunc-
tivitis, respectively. In addition, it would be useful to know 
how these ocular manifestations compare with other 
known COVID-19- like symptoms (such as fever and dry 
cough), how long they last for and when do they manifest 
when compared with the other COVID-19 symptoms. In 
addition, as a number of people are known to suffer from 
other chronic ocular symptoms, it would be useful to 
compare ocular symptoms before and during COVID-19 
state. The aims of the study were to examine the above 
points.
MATERIALS AND METHODS
Methods
An online questionnaire was adapted from validated 
questionnaires to examine the type and frequency of 
ocular and other symptoms in people who had been 
diagnosed with COVID-19. The questionnaire ascer-
tained the type and frequency of different already known 
symptoms of COVID-19 (dry cough, fever, fatigue, loss 
of smell/taste) as well as various ocular symptoms (sore 
eyes, watery eyes, gritty eyes, photophobia, itchy eyes). 
The time window of when and how long these symptoms 
were experienced was also compared with other known 
symptoms of COVID-19. The questionnaire explored if 
participants were chronic sufferers of the ocular symp-
toms (pre- COVID-19) and if they had experienced the 
same ocular symptoms during COVID-19 symptoms.
The majority of questions were adapted from validated 
questionnaires in the literature. These included the 
Ocular Surface Disease Index (OSDI) and Salisbury Eye 
Evaluation Questionnaire (SEEQ) that have been used 
in other COVID-19 studies.4 6 15 The questions relating 
to other COVID-19 symptoms were straightforward and 
have been used extensively in COVID-19 research. These 
included questions such as ‘what symptoms did you 
experience during COVID-19?’ and the list included the 
well- published symptoms relating to COVID-19. Once we 
had identified the relevant questions, the questionnaire 
underwent face validity. Three authors (SP, MV, HC) 
and two optometrists who were aware of the aims of the 
study completed the questionnaire to ascertain whether 
the questions addressed the research questions. The five 
people acted as participants and made notes on each 
question while completing the survey. The notes were 
pooled, and each question was analysed. Two of the ques-
tions were dropped as they were deemed to provide the 
same information. The questionnaire was then face vali-
dated again until it was approved. The questionnaire was 
then piloted on 20 ‘dummy participants’ who completed 
the questionnaire twice. Test–retest showed excellent 
repeatability of the results. We believed that this process 
of validation was adequate as the majority of the ques-
tions were from published validated questionnaires (ie, 
OSDI and SEEQ) as well as from published research on 
COVID-19 symptoms.
The online questionnaire was disseminated through 
university and our own institute’s websites and other 
social media avenues inviting people who had been 
infected with COVID-19 to take part.
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Participants
Anonymous online data were collected between 16 April 
and 20 July 2020. Self- reported data from 83 participants 
(n=83) over the age of 18 years who tested positive for 
COVID-19 were analysed. All patients provided informed 
consent prior to taking part in the study. Participants were 
treated in accordance with the Declaration of Helsinki. It 
was not appropriate or possible to involve patients or the 
public in the design, or conduct, or reporting, or dissem-
ination plans of our research.
RESULTS
Box 1 shows the questions and summary data of the 
participants (n=83) who completed the survey.
Statistical analysis
Associations between categorical variables (ie, gender) 
were assessed using the χ2 test. McNemar’s test compared 
the difference between paired nominal data for indi-
vidual eye symptoms before and during COVID-19.
COVID-19 symptoms
One hundred per cent of the participants who had been 
infected with COVID-19 experienced at least one of the 
four most common COVID-19 symptoms (fatigue, fever, 
dry cough, loss of smell/taste) (box 1). It should be 
noted that more than one symptom was experienced by 
82% of people.
Ocular symptoms
The most frequent ocular symptoms reported by partic-
ipants were photophobia (18%), sore eyes (16%) and 
itchy eyes (17%). Table 1 compares ocular symptoms 
before and during COVID-19 using McNemar’s test for 
paired comparisons. Sore eyes was reported significantly 
more during COVID-19 (p=0.002) compared with pre- 
COVID-19 state.
Duration of time frame for COVID-19 and eye symptoms
The χ2 analysis showed no significant difference in the 
duration of eye symptoms and the other symptoms of 
COVID-19 (p=0.147).
Differences between males and females
An independent t- test showed no significant difference 
between males and females for sore eyes (p=0.43), watery 
eyes (p=0.91) and itchy eyes (p=0.72).
Age groups
There was no significant effect of different age groups on 
ocular symptoms (p<0.05).
DISCUSSION
The four most reported COVID-19 symptoms in our 
study were fatigue (90%), fever (76%), loss of smell/taste 
(70%) and dry cough (66%). These agree with data from 
studies carried out on larger samples.
In people with confirmed COVID-19, a number of 
ocular symptoms indicative of viral conjunctivitis were 
reported. Of these, sore eyes was reported by 16%, and 
Box 1 Date of survey: 16 April to 20 July 2020
Participants (n=83) reported being infected by COVID-19 as 
confirmed by a healthcare provider
1. What is your age group?
Summary data: 18–29 years (14%), 30–39 years (21%), 40–49 
years (36%), 50–59 years (15%), 60–69 years (11%), 70–79 years 
(3%), over 80 years (0%).
2. What is your gender?
Summary data: males (35%), females (65%).
3. What symptoms indicative of COVID-19 did you experience?
Summary data:
 ► Fatigue (90%), fever (76%), dry cough (66%), loss of smell/taste 
(70%).
 ► Others included sore throat (53%), diarrhoea (28%), headaches 
(19%), shortness of breath (15%), myalgia/other pain (12%).
4. Do you suffer from any systemic diseases?
Summary data: hypertension, diabetes, asthma, lung disease 
(24%), no systemic disease (76%).
5. How long did you experience the symptoms indicative of COVID-19?
Summary data: less than 1 week (26%), between 1 and 2 weeks 
(36%), over 2 weeks (38%).
6. If you had eye symptoms during COVID-19, how long did they last 
for?
Summary data: over 2 weeks (20%), between 1 and 2 weeks (41%), 
less than a week (39%).
7. When did you experience the eye symptoms (compared with other 
symptoms indicative of COVID-19)?
Summary data: after all other symptoms (11%), within 1 week 
(65%), within 2 weeks (16%), 3 weeks or more before COVID-19 
onset (8%).
8. If you self- isolated, how long did you isolate for?
Summary data: 1 week (19%), 2 weeks (43%), longer than 2 weeks 
(36%), did not isolate/did not respond (2%).
Table 1 Data showing different ocular symptoms before 
and during COVID-19 in confirmed cases. Bonferroni 
correction was applied
Pre- 
COVID-19 
(n=83)
(n=yes (%))
Confirmed 
COVID-19 
(n=83)
(n=yes (%))
McNemar’s 
paired test
P value
Dry eye (ns) 19 (23) 12 (14) 0.08
Watery eyes (ns) 6 (7) 10 (12) 0.28
Mucous discharge 
(ns)
2 (2) 3 (4) 0.41
Changes in the 
eyelids (ns)
4 (2) 0 (0.0) 0.13
Gritty eyes (ns) 3 (4) 4 (5) 0.65
Sore eyes (s) 4 (5) 13 (16) 0.002*
Itchy eyes (ns) 12 (14) 14 (17) 0.65
Foreign body 
sensation (ns)
2 (2) 4 (5) 0.31
Photophobia (ns) 11 (13) 15 (18) 0.31
*significant value
ns, not significant; s, significant.
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this was significantly higher during pre- COVID-19 state. 
Although dry eye was reported by more people before 
COVID-19 state (23%), the prevalence decreased during 
COVID-19 state (14%), as did changes in the eyelids. This 
change was surprising. However, it did not reach statis-
tical significance. It is possible that this non- significant 
decrease might have been influenced by environmental 
conditions including lack of exposure to dry eye determi-
nants such as pollution, and so on, as participants would 
have stayed at home during their infection state. The 
change in eyelids was also non- significant (2% to 0%).
Mucopurulent discharge, indicative of bacterial infec-
tion, showed low prevalence rate, which did not change 
significantly during COVID-19 state. Although other 
ocular symptoms such as watery eyes, itchy eyes and photo-
phobia were relatively high, these did not reach statistical 
significance when compared with pre- COVID-19 state. 
While it is important that ocular symptoms are included 
in the list of possible COVID-19 symptoms, we argue that 
sore eyes should replace ‘conjunctivitis’ as it is important 
to differentiate from symptoms of other types of infec-
tions, such as bacterial infections, which manifest as 
mucous discharge or gritty eyes.1
Our data show that 81% of participants reported to have 
experienced ocular symptoms within 2 weeks of other 
COVID-19 symptoms, and 80% reported that they lasted 
for less than 2 weeks. The timing when ocular symptoms 
occur in comparison to other COVID-19 symptoms varies 
widely. Literature suggests that this ranges from around 
8 days before other COVID-19 symptoms (cough/fever, 
and so on) to 43 days after.6–11 16–29 The reasons as to why 
this occurs are not obvious and further work is required 
to explore the reasons for this.
The potential mechanism for SARS- CoV-2 infection 
in the eye is important. SARS- CoV-2 invasion of healthy 
human cells is reliant on the host receptor, ACE2, 
hypothesised to infect cells using two potential routes.30 
The traditional route of entry is through the spike (S) 
protein of the virus, which binds to the ACE2 receptor 
as a homodimer.31 The S protein is then cleaved by the 
transmembrane protease, TMPRSS2, into S1 and S2 
subunits.32 The latter is responsible for membrane fusion 
to allow entry into the cell via cathepsin L and cathepsin 
B- mediated endocytosis.33 34 An alternate hypothe-
sised route for SARS- CoV-2 infection into human cells 
is the ability to bind to the ACE2- BoAT1 heterodimeric 
complex at the human cell surface.31 BoAT1 (SLC6A19), 
traditionally considered to be an amino acid transporter 
in the small intestine, has gained significant interest as 
ACE2 is also responsible for the membrane trafficking of 
BoAT1.35 While ACE2 and TMPRSS2 expression has been 
studied in the eye, given the early stage of studies on 
BoAT1 in relation to SARS- CoV-2 infection, the protein 
has not yet been identified in the eye.
SARS- CoV-2 is typically considered to be transmitted by 
airborne dissemination of respiratory droplets through 
direct or indirect contact. Many viruses, such as avian 
influenza virus H7, have been shown to cause highly 
infectious viral conjunctivitis, and conjunctiva is hypoth-
esised to be an important entry point for the infection.36 
Murine coronavirus has been shown in previous studies 
in China to demonstrate that up to a third of patients with 
COVID-19 have suffered from ocular conditions associ-
ated with conjunctivitis, such as watery and sore eyes.6 7 37 
While there are no studies, as yet, that have determined 
conclusively the mechanism through which SARS- CoV-2 
can infect the conjunctiva, the eye is known to have an 
internal (aqueous humour, iris, retina) and external 
(conjunctiva, cornea) intraocular renin- angiotensin 
system.38 There is still controversy in the literature 
regarding the presence of the machinery needed for 
SARS- CoV-2 infection in the conjunctiva. Some studies 
have reported an expression of ACE2 and TMPRSS2 in 
the human conjunctival and pterygium cell lines and 
tissue.39 40 Others show negligible ACE2 expression in the 
human conjunctiva.41 There is, therefore, a great need 
to further investigate the possibility that SARS- CoV-2 can 
directly infect the conjunctiva and cause the ocular symp-
toms we observe in participants in this study. Another 
possibility is that the cornea is the site of SARS- CoV-2 
infection. In cornea limbal stem cells from healthy human 
participants and murine cornea, high mRNA expression 
of ACE2 and TMPRSS2 has been identified, suggesting 
that SARS- CoV-2 may infect the ocular surface via the 
cornea using the traditional ACE2- TMPRSS2- mediated 
mechanism of cell entry.39 40 42 It is, therefore, possible 
that SARS- CoV-2 can infect the ocular surface via the 
cornea using the traditional ACE2- TMPRSS2- mediated 
mechanism of cell entry. Given the neuronal expres-
sion of ACE2 and TMPRSS2, it is possible that this type 
of infection may allow the spread of the virus through 
the nose, lungs, bloodstream, and through the nervous 
system (via the trigeminal nerve) to potentially cause the 
COVID-19 symptoms documented in participants.43
There is a strong association between the neuroinva-
sive potential of SARS- CoV-2 and the onset of respiratory 
failure in patients with COVID-19.44 In both symptom-
atic and asymptomatic patients with SARS- CoV-2, nasal 
swabs have a significantly higher viral load than throat 
swabs. Indeed, Hu et al found that SARS- CoV-2 was iden-
tified in eye swabs for 2 weeks after the nasopharyngeal 
swabs turned negative.45 In addition, viruses similar to 
SARS- CoV-2 have been found in tears of patients infected 
with the virus.46 As dry cough is one of the predominant 
observed symptoms in participants, and that ocular mani-
festations occur simultaneously with other COVID-19 
symptoms, another possibility is that lacrimal drainage 
from the conjunctival sac into the nasal cavity allows the 
spread of SARS- CoV-2 into the upper respiratory tract as 
a potential mechanism of virus spread. By using a murine 
coronavirus, it was identified that the virus has specific 
retinotropism, irrespective of whether administered 
via intranasal, intravitreal or intracerebral route.47 48 In 
addition, in keeping with other studies, we demonstrate 
a large number of participants with COVID-19 symp-
toms indicate a loss of smell and taste.49–51 This is not 
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surprising given the association between viral infection 
and/or upper respiratory tract infections and ageusia 
and anosmia.52 Interestingly, the machinery for the main 
route of entry for SARS- CoV-2, ACE2 and TMPRSS2, has 
been identified to colocalise with the epithelium in the 
oral and nasal cavities where taste and smell are governed 
respectively.53 54 It is, therefore, possible that the spread 
of SARS- CoV-2 through lacrimal drainage of the tears 
enables the virus to bind to ACE2 in the oral and nasal 
cavities to blunt taste and smell.
Our findings suggest that ‘sore eye’ should be used 
to ascertain ocular symptoms linked to COVID-19. The 
study has a few limitations. Although the number of 
people in this study sample is relatively small, the preva-
lence of other symptoms of COVID-19 agrees with those 
in the literature. This should be confirmed with a larger 
scale study. We did not collect data on health literacy 
apart from participants’ self- reporting on any systematic 
diseases. It is also important to note that ocular symp-
toms might have been under- reported in the presence of 
other more serious manifestations of the disease. We also 
did not collect data on prior eye disease or collect any 
further data on self- reported vision loss or the presence 
of any other complicated eye diseases. In addition, it is 
possible that the online questionnaire and social media 
approach may have biased responses from digital literate 
participants. It is possible that people who are not digital 
literate were excluded from the study. It is also possible 
that these people might be older and may indeed have 
presented with different prevalence rates of ocular symp-
toms before and during COVID-19. This would require 
face- to- face or telephone interviews and would form the 
basis of a future study.
In conclusion, this is the first study to investigate the 
various eye symptoms indicative of conjunctivitis in rela-
tion to COVID-19, their time frame in relation to other 
well- known COVID-19 symptoms and their duration. We 
show that sore eyes was the most significant ocular mani-
festation of COVID-19 (compared with pre- COVID-19 
state) and that ocular symptoms manifest at the same 
time as other COVID-19 symptoms. Our data agree with 
the fact that there has been an increase in ‘sore eyes’ as 
increasing trending Google search term over the past 10 
months.55
The term ‘conjunctivitis’ does not differentiate 
between its different types which manifest as different 
ocular symptoms, including mucopurulent discharge, 
and may mislead. It is therefore important the clinicians 
ascertain the correct symptoms that manifest in the eye 
due to COVID-19 infection.
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